There is a growing consensus that alcohol-related liver disease (ALD) should be considered a metabolic disorder under the influence of the gut-liver axis. Metabolome data have highlighted fatty acid-activated G protein-coupled receptors (GPCRs) as the main affected pathways, where the relationship of G-protein-coupled receptor 119 (GPR119) with ALD remains unexplored.
The National Center of Neurology and Tokyo University of Science in Japan have jointly developed new μ-opioid receptor antagonists potentially useful for the treatment of opioid dependence.
Endevica Bio Inc. has disclosed cyclic peptides acting as melanocortin MC1 and/or MC5 and/or MC3 and/or MC4 receptor agonists. They are reported to be useful for the treatment of substance abuse and dependence and diabetes.
